Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Customized CXL

Poster Details

First Author: T.Seiler SWITZERLAND

Co Author(s):    I. Fischinger   T. Koller   T. Seiler              

Abstract Details

Purpose:

To investigate safety and efficacy of tomography-customized corneal crosslinking and to prove hypothesis of focal weakening in primary corneal ectasia.

Setting:

Institut für Refraktive und Ophthalmo-Chirurgie (IROC), Zurich, Switzerland

Methods:

In a prospective study, 22 eyes of 22 patients were treated with customized crosslinking for halting the progression of keratectasia and followed for 12 months. Standard 0.1% riboflavin in 12% dextran was applied for 30 min. The irradiation-profiles were centred on the maximum posterior float with energy fluencies of 10mW/cm². The total energy applied to the corneas had a maximum of 15J/cm². BSCVA, Scheimpflug imaging, topography, endothelial cell count, AS-OCT and slit lamp examination were collected as pre- and postoperative parameters.

Results:

BSCVA increased by -0.08 ± 0.16logMAR (p=0.17). No eye had a loss of more than 1 Snellen line. Kmax decreased by -0.80 ± 1.08D (p=0.11). Corneal pachymetry decreased by -9 ± 11µm (p=0.05), the endothelial cell count did not change significantly (p=0.44). Average epithelium healing time was 2.63 ± 0.48. One eye showed sterile infiltrates, no other complications occurred

Conclusions:

Customized corneal crosslinking is a promising approach for halting the progression of keratectasia. Due to the smaller abrasion zone necessary, customized CXL presents a less invasive procedure for the patient. These prelimited results in terms of safety and efficacy are comparable to conventional crosslinking. Larger study groups are needed to prove safety and validate the efficacy.

Financial Disclosure:

NONE

Back to Poster listing